TABLE 1.

Development of diagnostic marker under Guselkumab/Dupilumab combination therapy

	Naïve	Guselkumab/Dupilumab, 10 weeks	Guselkumab/Dupilumab, 80 weeks
VAS	10/10	1–2/10	1–2/10
SCORAD	81	6.6	8
BSA	90%	9%	10%
CRP	17 mg/L	12.1 mg/L	12 mg/L
IgE	4362 UI/ml	2203 UI/ml	1555 UI/ml
Monocytes	11%	8.5%	6.2%
Neutrophils	64.9%	54.1%	62%
Eosinophils	1.6%	1.6%	0.7%

Abbreviations: BSA, body surface area; CRP, C‐reactive protein; IgE, immunoglobulin E; VAS, visual analogue scale.